Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIGH-VIS Trial
NCT04796636Phase 1Unknown
- Sponsor
- Melbourne Health
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium ascorbate in septic shock (3 arms), sponsored by Melbourne Health. Primary endpoint: Time to cessation of vasopressor support at 7 days. Status: unknown.
02
Drugs
sodium ascorbate
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04796636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796636.